Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Johnson & Johnson's Nipocalimab Shows Sustained Efficacy in SLE Phase 2 JASMINE Study

Johnson & Johnson announced positive Phase 2 JASMINE study results for nipocalimab in moderate-to-severe systemic lupus erythematosus (SLE). The study met its primary endpoint at Week 24, showing a reduction in disease activity measured by SRI-4b. Efficacy was sustained through Week 52, with greater responses observed in autoantibody-positive patients, who represent about 80% of SLE cases. At Week 52, nipocalimab 15 mg/kg demonstrated superior SRI-4b response (53.6% vs 39.7%, p=0.020) and LLDAS achievement (37.5% vs 20.5%, p=0.013) compared to placebo. The drug, an FcRn blocker, targets pathogenic IgG autoantibodies and showed a consistent safety profile. These findings support its continued investigation, with a Phase 3 study underway and Fast Track Designation granted by the FDA.

• The Phase 2 JASMINE study successfully met its primary endpoint at Week 24, demonstrating a greater proportion of patients receiving nipocalimab 15 mg/kg achieving an SRI-4b response (53.5%) compared to placebo (46.7%), with an odds ratio of 1.6 (90% CI: 0.9-2.9). This initial proof-of-concept for an FcRn blocker in SLE highlights nipocalimab's ability to reduce disease activity early in treatment, setting the stage for its potential as a targeted therapeutic option.
• Efficacy was sustained through Week 52, with nipocalimab 15 mg/kg showing significantly greater SRI-4b response (53.6% vs. 39.7%; p=0.020) and Lupus Low Disease Activity State (LLDAS) achievement (37.5% vs. 20.5%; p=0.013) compared to placebo. Notably, autoantibody-positive patients, a large subpopulation of SLE, showed even more pronounced benefits, with SRI-4 response rates of 58.2% vs. 36.1% (p=0.004) and LLDAS of 38.9% vs. 18.0% (p=0.012) at Week 52.
• Nipocalimab exhibited a safety profile consistent with previous studies, with no new safety signals identified. Common adverse reactions included nasopharyngitis, headache, urinary tract infection, and nausea. The promising results and safety data have contributed to nipocalimab receiving Fast Track Designation from the U.S. FDA for SLE in January 2026, underscoring its potential to address significant unmet needs in this debilitating autoimmune disease and expedite its development pathway.

Nipocalimab's JASMINE Phase 2 Results Show Sustained SLE Activity Reduction

Recent clinical trials and real-world studies have demonstrated promising therapeutic advances across multiple treatment modalities for systemic lupus erythematosus. These investigations span from novel targeted biologics to innovative cellular therapies, providing comprehensive evidence for treatment optimization in diverse patient populations.

• ALLEGORY Phase 3 Trial (NCT04963296) evaluated obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, in 303 patients with active SLE. The study achieved superior SRI-4 response rates of 76.7% versus 53.5% with placebo (P<0.001), with benefits across all key secondary endpoints including BILAG-based Composite Lupus Assessment response and sustained glucocorticoid reduction. Adverse events occurred in 88.7% of obinutuzumab patients versus 81.5% with placebo, with serious adverse events in 15.9% versus 11.9% respectively.

• POETYK SLE-1 and SLE-2 Phase 3 Trials (NCT05617677, NCT05620407) investigated deucravacitinib, a first-in-class oral selective allosteric tyrosine kinase 2 inhibitor, in patients aged 18-75 years with active SLE. The global, randomized, double-blind trials randomized patients 3:2 to receive deucravacitinib or placebo for 52 weeks with SLE Responder Index-4 response as the primary endpoint. An optional 104-week open-label extension allows comprehensive long-term safety assessment.

• Telitacicept Phase 3 Trial (18C010) demonstrated significant efficacy in 335 Chinese adults with active SLE, achieving 67.1% versus 32.7% modified SRI-4 response with telitacicept versus placebo (P<0.001). The dual BLyS/APRIL inhibitor showed 70.1% versus 40.5% achievement of ≥4 point SELENA-SLEDAI reduction. Safety profile revealed higher adverse event rates with telitacicept (74.9% versus 50.0%), primarily upper respiratory tract infections (31.7%), reduced serum IgG (15.6%), and injection-site reactions (12.6%).

• CASTLE Phase 1/2a Trial (NCT06347718) investigated zorpocabtagene autoleucel CAR-T cell therapy in 10 SLE patients, achieving remarkable 90% DORIS remission rates at 24 weeks. Following lymphodepletion with cyclophosphamide and fludarabine, patients received single CAR-T infusions with no cytokine release syndrome higher than grade 2 and no immune effector cell-associated neurotoxicity syndrome. All patients remained free of glucocorticoids and immunosuppressive treatments throughout the 24-week observation period.

• REVEAL Study (NCT07215754) assessed anifrolumab in 236 patients across 25 Italian tertiary centers, demonstrating 26% remission rates and 57% LLDAS5 achievement at 6 months. The type I interferon receptor antagonist showed manageable safety with 108 adverse events during 6-month follow-up, predominantly infections (77%), with 5 serious adverse events requiring hospitalization.

• Iscalimab Phase 2 Trial (NCT03610516) in 57 patients with proliferative lupus nephritis showed superior proteinuria reduction of 63.1% versus 36.3% with placebo at week 24. The anti-CD40 monoclonal antibody demonstrated statistically significant 42.1% reduction in urine protein-to-creatinine ratio with generally well-tolerated safety profile, though seven serious adverse events occurred in the treatment arm versus four with placebo.

FcRn Blockade: An Emerging Mechanism for Systemic Lupus Erythematosus

Recent literature reveals several innovative mechanisms of action emerging for SLE treatment, moving beyond traditional immunosuppression toward more targeted therapeutic approaches. These emerging therapies address specific pathways involved in SLE pathogenesis, offering potential for improved efficacy with reduced side effects.

• cGAS-STING Pathway Inhibition — The cyclic GMP-AMP synthetase-interferon gene stimulating factor innate immune pathway represents a novel therapeutic target, with serum levels of cGAS, STING, and type I interferon significantly elevated in SLE patients, and over 20 inhibitors currently under development

• Protein Phosphatase 2A (PP2A) Restoration — SLE monocytes demonstrate selective downregulation of PP2A structural subunit PPP2R1A, and pharmacological activation through FTY720 significantly curtails exaggerated immune responses by mitigating dysregulated innate immunity

• CD11b Activation — Pharmacologic activation with clinical-stage agonist ONT01 suppresses soluble urokinase plasminogen activator receptor production and reduces systemic inflammation, with genetic coding variants of ITGAM significantly increasing SLE risk through reduced CD11b activity

• SLC15A4 Inhibition — First-in-class functional inhibitors targeting this endolysosome-resident transporter suppress TLR7-9 and NOD signaling pathways critical for SLE development, representing a novel druggable target for autoimmune conditions

• Caspase-1 Inhibition — Selective targeting with pralnacase effectively ameliorates both systemic and renal SLE manifestations primarily through suppression of IL-18-mediated inflammation, with IL-18 identified as the primary pathogenic driver rather than IL-1

• Mesenchymal Stromal Cell Therapy — MSCs provide context-dependent immunomodulation showing superior efficacy in suppressing pathogenic autoantibodies and increasing protective regulatory T cells compared to conventional multi-target pharmacotherapy

• Telitacicept Dual Blockade — This immunosuppressant simultaneously blocks B-cell stimulating factors and proliferation-inducing ligands, with specific protein biomarkers (XPNPEP3, SRSF5, SRSF6, WARS1, IDH1, ITLN1) correlating with therapeutic efficacy

Addressing Persistent Unmet Needs in Moderate-to-Severe SLE

Recent literature highlights persistent gaps in SLE management despite therapeutic advances. The most significant unmet needs center on symptom management, disease control, and care accessibility across diverse patient populations.

• Fatigue remains severely under-addressed despite being the most prevalent symptom affecting 84.9% of patients, with significant unmet needs in both pharmacological and non-pharmacological management approaches

• Poor disease control persists broadly with only 7.9% of patients reporting no disease flares over five years, contrasting sharply with reported remission rates and indicating fundamental gaps in achieving sustained disease stability

• Quality of life impact remains substantial with mean lupus burden scores of 6.94 on a 0-10 scale, particularly affecting fatigue management and physical functioning domains

• Cutaneous lupus erythematosus patients face treatment limitations due to lack of FDA-approved CLE-specific therapies, resulting in restricted availability and insurance coverage for patients without systemic involvement

• Care disparities exist across healthcare settings with antimalarial utilization rates of only 35% among patients not treated by rheumatologists compared to 81% for those under rheumatologist care

• Emergency department presentations reveal diagnostic delays with 54.4% of patients receiving their initial SLE diagnosis during ED visits, highlighting gaps in early recognition and screening

• Ethnic minorities experience worse disease outcomes with non-Spaniard patients showing significantly higher disease activity scores and lower remission rates compared to Spaniard patients

• Patient-physician communication gaps persist requiring improved integration of patient-centered strategies and better communication frameworks to optimize disease management

Nipocalimab's SLE Success: Expanding FcRn's Autoimmune Reach

The recent positive Phase 2 JASMINE study results for nipocalimab in moderate-to-severe systemic lupus erythematosus mark a significant advancement in the treatment landscape for this complex autoimmune disease. Systemic lupus erythematosus, characterized by a diverse array of symptoms and often driven by pathogenic IgG autoantibodies, represents a substantial unmet medical need. Nipocalimab, as a neonatal Fc receptor (FcRn) blocker, offers a targeted approach by accelerating the catabolism of these autoantibodies, a mechanism already validated in other IgG-mediated conditions like myasthenia gravis. The sustained efficacy observed through Week 52, particularly in the large autoantibody-positive patient population, underscores the potential for meaningful disease control.

This success in SLE positions nipocalimab as a versatile asset within Johnson & Johnson's immunology portfolio, extending its reach beyond its recent approval in generalized myasthenia gravis. The 'pipeline in a product' strategy, leveraging a single drug across multiple high-value indications, is a powerful commercial driver. However, the FcRn inhibitor class is becoming increasingly crowded, with several competitors already approved or in advanced stages of development. Nipocalimab's Phase 3 program in SLE will need to clearly demonstrate a compelling profile in terms of efficacy, safety, and patient convenience to differentiate itself in this competitive environment.

While FcRn inhibitors generally exhibit a favorable safety profile, considerations for long-term use in a chronic condition like SLE are paramount. The transient nature of IgG reduction necessitates continuous dosing, which could influence patient adherence and the cumulative risk of adverse events such as infections or potential metabolic changes like hypoalbuminemia. Future research will need to further elucidate optimal dosing strategies and long-term safety, ensuring that this innovative therapeutic approach translates into sustained clinical benefit for patients. The Fast Track Designation from the FDA highlights the urgency and potential impact of this therapy, setting the stage for a pivotal Phase 3 trial that could redefine SLE management.